

**Centralità
della persona,
sinergia
dei saperi,
omeopatia**



Venerdì 06 giugno 2014
14.30-19.30
Sabato 07 giugno 2014
9.00-13.00; 14.30-19.30

Milano - Società Umanitaria

La Similitudine come regola di natura


Paolo Bellavite, Marta Marzotto, Debora Olioso, Elisabetta Moratti
Università di Verona



Milano- 6 giugno 2014

© P. Bellavite, Università di Verona





C.F.S. Hahnemann

LA «LEGGE TERAPEUTICA»

L'ALTRA MEDICINA studio/14

C. F. SAMUEL HAHNEMANN
VI EDIZIONE DELL'
ORGANON
DELL'ARTE DEL GUARIRE
NELLA TRADUZIONE DI
G. RICCAMBONI L'OPERA
CAPITALE DELL'OMEOPATIA

*“La grande, la sola legge terapeutica
della natura: cura per mezzo della
similitudine dei sintomi!”*

ORGANON, PAR. 7





A STUDY OF THE SIMILE IN MEDICINE

Boericke & Tafel, Philadelphia 1936



Linn John Boyd
(1895-1975)
Professor of Medicine



www.paolobellavite.it/libri



**Centralità
della persona,
sinergia
dei saperi,
omeopatia**



Venerdì 06 giugno 2014
14.30-19.30
Sabato 07 giugno 2014
9.00-13.00; 14.30-19.30

Milano - Società Umanitaria

La Similitudine come regola di natura


- 
- L e regole della Natura e la complessità fondamentale della vita
 - Modello a rete: omeodinamica, omeopatologia, omeoterapia
 - Il Simile nello studio sperimentale



LA «PHYSIS» DI IPPOCRATE

“Η φυσις αυτοματη ταυτα επισταται πονεει αναστηναι, κινευμενος πονεει αναπαυσασθαι, και αλλα τοιαυτα εχει η φυσις ιητρικης”.

“La ‘physis’ fa tutto ciò di per sé. Se uno siede e sente un dolore, la ‘physis’ lo induce ad alzarsi. Se uno cammina e sente un dolore, essa lo induce a fermarsi. Altre cose come queste sono dovute alla physis’.





Ippocrate
(460-377 B.C.)


“Sulla dieta”, da Littré’s Oeuvres Complètes d’Hippocrates, Paris, 1839, VI, 490, 15.



LA “PHYSIS”




- * “*Ch’i*” degli antichi cinesi
- * “*vis medicatrix naturae*” di Ippocrate
- * “*archèus*” di Paracelso e di Helmont
- * “*anima*” di Eraclito, Stahl e di altri
- * “*viriditas*” di Ildegarda
- * “*forza vitale*” di Hahnemann




«PHYSIS», «FORZA VITALE», «OMEODINAMICA»

Mantenimento (e re-integrazione) dello stato di salute



Controllo dinamico
delle **variabili fisiologiche**,
della **integrità** delle strutture ai vari livelli
e della **identità** biologica





“DYNAMIS” E MALATTIA SEC: HAHNEMANN

C.F.S. Hahnemann

*“Ogni malattia (non di spettanza della chirurgia) consiste in una perturbazione patologica **dynamica** della nostra forza vitale”*
(Organon, 1810, par. 29)


“La restitutio ad integrum del principio vitale presuppone necessariamente il ritorno alla salute di tutto l’organismo”
(Organon, 1810, par. 12)



PAROLE-CHIAVE DELL'OMEODINAMICA

DINAMICITA', DYNAMIS:

- a) “capacità di **cambiare nel tempo**” la posizione e l’attività nello spazio dell’energia. Oscillazioni, ritmi.
- b) “capacità di gestire **l’energia (dynamis)** da cui il sistema dipende”




COMPLESSITÀ:

Con-plesso= “tenuto insieme” da comunicazioni e interazioni. Il tutto è più della somma delle parti.

- Struttura a rete e frattale
- Capacità di auto-organizzazione, emergenza di nuove forme-connessioni
- NON-linearità



Nonlinear allostatic network in response to stress




A Model for Homeopathic Remedy Effects: Low Dose Nanoparticles, Allostatic Cross-Adaptation, and Time-Dependent Sensitization in a Complex Adaptive System

Iris R. Bell and Mary Koithan – BMC Compl. Altern. Med 2012




ESEMPI DI RETI

SISTEMA NEUROIMMUNOENDOCRINO




→ STIMULATION
→ INHIBITION



CYTOKINE
NETWORK




5 ELEMENTI



Insulin Receptor Pathway




“NON-MOLECULAR” BIOLOGIC SIGNALS




| SIGNALS | EXAMPLES |
|---------------------------|----------------------------------|
| <i>BETWEEN CELLS</i> | |
| Low-frequency e.m. fields | Cell growth |
| Piezoelectricity | Bone trabeculae |
| Light | Leukocytes, DNA (biophotons) (?) |
| <i>INSIDE THE CELLS</i> | |
| Electric potentials | Ionic channels, nerve fibers |
| Mechanical waves | Actin fibers, muscle |
| Low-frequency e.m. fields | G-proteins, membrane pumps |



L'AUTO-ORGANIZZAZIONE DELLE RETI DINAMICHE COSTITUISCE UN LIMITE ALLA PRETESA DI REGOLAZIONE FARMACOLOGICA





LO SCOPO PRINCIPALE

L'ALTRA MEDICINA studio/14

C. F. SAMUEL HAHNEMANN
VI EDIZIONE DELL'
ORGANON
DELL'ARTE DEL GUARIRE
NELLA TRADUZIONE DI
G. RICCAMBONI L'OPERA
CAPITALE DELL'OMEOPATIA

“Scopo principale ed unico del medico è di rendere sani i malati, ossia, come si dice, di guarirli” (ORGANON, PAR. 1)

Nota al Par. 1: “E non il congetturare ed erigere a sistemi (...) vuote idee ed ipotesi sull'intima essenza dei processi vitali e sull'origine delle malattie nell'invisibile interno del nostro corpo...”

**Centralità
della persona,
sinergia
dei saperi,
omeopatia**



Venerdì 06 giugno 2014
14.30-19.30
Sabato 07 giugno 2014
9.00-13.00; 14.30-19.30

Milano - Società Umanitaria

La Similitudine come regola di natura

- Le regole della Natura e la complessità fondamentale della vita
- Modello a rete: **omeodinamica, omeopatologia, omeoterapia**
- Il Simile nello studio sperimentale





Available online at www.sciencedirect.com

ScienceDirect

journal homepage: www.elsevierhealth.com/journals/ctim



A dynamic network model of the similia principle



Paolo Bellavite^{a,*}, Debora Olioso^a, Marta Marzotto^a,
Elisabetta Moratti^a, Anita Conforti^b

^a Department of Pathology and Diagnostics, University of Verona, 37134 Verona, Italy

^b Department of Public Health and Community Medicine, University of Verona, 37134 Verona, Italy

Available online 8 September 2013

KEYWORDS

Homeopathic theory;
Similia principle;
Network model;
Complexity science;
Homeopathic
methodology;
Symptoms analysis



Summary The use of drugs in high dilutions and the principle of similarity (or "similia") are two basic tenets of homeopathy. However, the plausibility of both is a subject of debate. Although several models have been proposed to explain the similia principle, it can be best understood and appreciated in the framework of complexity science and dynamic systems theory. This work applies a five-node Boolean network to show how self-organization and adaptation are relevant to rationalizing this traditional medical principle. Simulating the trajectories and attractors of the network system in the energy state-space provides a rudimentary and qualitative illustration of how targeted external perturbations can have pathological effects, leading to permanent, self-sustaining alterations. Similarly, changes that conversely enable the system to find its way back to the original state can induce therapeutic effects, by causing specific shifts in attractors when suitable conditions are satisfied. Extrapolating these mechanisms to homeopathy, we can envisage how major changes in the evolution of homeodynamic systems (and, eventually, healing of the entire body) can be achieved through carefully selected remedies that reproduce the whole symptom pattern of the ill state.

© 2013 Elsevier Ltd. All rights reserved.




ANATOMIA, FISIOLOGIA E PATOLOGIA DI UN «SISTEMA»

(Bellavite et al 1998-2013)



«SYMPTOMS» ARE ALWAYS MANIFESTATIONS OF DIRECT OR INDIRECT CHANGES OF SOME NODES OF THE NETWORK




«ILLNESS» or «DISEASE»



C. F. SAMUEL HAHNEMANN
 VI EDIZIONE DELL'
ORGANON
 DELL'ARTE DEL GUARIRE
 NELLA TRADUZIONE DI
 G. RICCAMBONI L'OPERA
 CAPITALE DELL'OMEOPATIA


Organon, Par. 14,15



“Non vi è alcuna malattia né alcuna alterazione morbosa nell'interno dell'organismo, che non si dia a riconoscere per mezzo di segni (sintomi) al medico, che attentamente osserva”


“Il male della forza vitale, vivificatrice del nostro corpo, perturbata morbosamente e immaterialmente nell'interno invisibile, e l'insieme dei sintomi, da essa determinati nell'organismo e percepibili all'esterno e costituenti la malattia, formano un tutt'uno, sono la stessa cosa”





Frida Kahlo (1907-1954),
La colonna spezzata, 1944, olio su tela


Alexis Carrel
L'homme, cet inconnu.
Plon, Paris, 1935




“L'uomo è un tutto indivisibile, che si manifesta con delle attività fisico-chimiche, fisiologiche e psicologiche”



GRADI DI LIBERTA' E FORMAZIONE DI ATTRATTORE



32 conformazioni possibili



Cambiamenti deterministici

Attrattore
dinamico





SPAZIO DELLE FASI (DEGLI STATI O DELL'ENERGIA)

Rappresentazione grafica dello stato di un sistema in cui ad ogni asse è associata una variabile dinamica.

Stati

+ lontani

dall'equilibrio

(alta spesa energetica)



Stati

+ stabili


(bassa spesa

energetica)



<----- Serie di stati possibili, tempo, progressione, ecc. ----->





C.F.S. Hahnemann

MALATTIE E “DINAMICA” SEC. HAHNEMANN

“La malattia e la guarigione si sviluppano solo attraverso influenze dinamiche”

C.F.S. Hahnemann, Organon, 5th ed, par. 86.

“Le medicine agiscono non anatomicamente ma dinamicamente”

C.F.S. Hahnemann, Über die Kraft kleiner Gaben der Arzneien
überhaupt un der Belladonna insbesondere. *Hufeland's Journal* 13, 153,
1801.







THE SPACE OF STATES, OR SPACE OF ENERGY

Far-from equilibrium
patterns - high energy
expenditure

↑
More stable patterns - low energy expenditure
↓






C.F.S. Hahnemann

Organon (VI ed) Par. 13


“La malattia – che non cade nel campo della manuale chirurgia – (come avviene per gli allopatici) non è da considerare come un quid (materia peccans) separato dall’organismo vivente e dal principio dinamico che lo vivifica”







PERTURBATIONS AND MUTATIONS (OMEOPATHOLOGY)

Far-from equilibrium
patterns - high energy
expenditure



MALATTIA COME FENOMENO DINAMICO NELLO SPAZIO DELL'ENERGIA






C.F.S. Hahnemann

INVALIDITÀ DELLA FORZA VITALE NELLE MALATTIE CRONICHE E OMEOPATIA

(CFS. Hahnemann: Die Chronischen Krankheiten, 2nd Ed., iv, 1838)

“Nelle malattie croniche la vera salute non può essere riportata dalla sola forza vitale. Tuttavia, è altrettanto certo che se tale forza è resa più valida dalla vera arte della guarigione (quella omeopatica), guidata dall’umana ragione, essa può sopraffare e superare (quindi curare) non solo le malattie rapide e transitorie, ma anche quelle croniche (...).





C.F.S. Hahnemann

IL “SIMILE” di Hahnemann

Versuch über ein neues Princip zur Auffindung der Heilkrafte der Arzneisubstanzen –
Hufeland's Journal 2, 381, 1796.

.

“Uno imita la natura, che talvolta guarisce le malattie croniche aggiungendo un'altra malattia, e quindi impiega nella malattia (preferibilmente cronica) quel farmaco che si trova nella posizione di poter eccitare un'altra malattia artificiale più simile possibile a quella naturale, che sarà guarita: similia similibus”






CONCEPTUAL MODEL OF HOMEOTHERAPY



Far-from equilibrium
patterns - high energy
expenditure

"Se in un caso di malattia cronica si dà una medicina la cui azione primaria diretta corrisponde alla malattia, l'azione secondaria indiretta è esattamente lo stato del corpo che si desidera ottenere..."

C.F.S. Hahnemann, *Hufeland's Journal* 2, 381, 1796



More
stable
patterns
- low energy
expenditure






CONCEPTUAL MODEL OF HOMEOTHERAPY



Far-from equilibrium
patterns - high energy
expenditure



Uno imita la natura, (...) e quindi impiega nella malattia (preferibilmente cronica) quel farmaco che si trova nella posizione di poter eccitare un'altra malattia artificiale più simile possibile a quella naturale, che sarà guarita: similia similibus
C.F.S. Hahnemann, *Hufeland's Journal* 2, 381, 1796



Omnia venenum sunt

«*Omnia venenum sunt: nec sine veneno quicquam existit. Dosis sola facit, ut venenum non fit.*»


«Tutto è veleno, nulla esiste che non sia veleno. Solo la dose fa che il veleno abbia effetto»

(Paracelso,
Responsio ad quasdam accusationes & calumnias suorum aemulorum et obtrectatorum. Defensio III. Descriptionis & designationis nouorum Receptorum.)

Mitridate, re del Ponto
(132-63 a.c.)



LA REGOLA DEL “VALORE INIZIALE” (DI WILDER)




Bellavite et al. ECAM Journal 2007




PROTEIN FOLDING IN THE ENERGY LANDSCAPE


A Energy landscape of different protein conformations



B Allosteric regulator




C




PROTEIN FOLDING IN THE ENERGY LANDSCAPE


(Bellavite et al., *Homeopathy* 2015)

A Energy landscape of different protein conformations



B Energy landscape of different protein conformations






C.F.S. Hahnemann

LA FORZA VITALE DALLA TRADIZIONE ALLA SCIENZA

(CFS. Hahnemann: Die Chronischen Krankheiten, 2nd Ed., iv, 1838)




«È sempre questo potere, la forza vitale, che scaccia il nemico, nel caso che sia supportata dai medicinali (...).»




Legami idrogeno tra cluster d'acqua e macromolecole

Bellavite et al., Homeopathy January 2014

A. Internal H-bond



B. H-bond to water



Closed structure

(e.g. Inactive enzyme)

Open structure

(e.g. Active enzyme)




The Role of Water H-Bond Imbalances in B-DNA Substate Transitions and Peptide Recognition

Khesbak , Olesya Savchuk , Satoru Tsushima , and Karim Fahmy

Division of Biophysics, Institute of Radiochemistry, Helmholtz-Zentrum Dresden, Germany


J. Am. Chem. Soc., 2011, 133 (15), pp 5834–5842




Risonanza stocastica

Bellavite et al., Homeopathy 2014

A



B



**Centralità
della persona,
sinergia
dei saperi,
omeopatia**



Venerdì 06 giugno 2014
14.30-19.30
Sabato 07 giugno 2014
9.00-13.00; 14.30-19.30

Milano - Società Umanitaria

La Similitudine come regola di natura

- Le regole della Natura e la complessità fondamentale della vita
- Modello a rete: omeodinamica, omeopatologia, omeoterapia
- Il Simile nello studio sperimentale






Saggio su un nuovo principio

C.F.S. Hahnemann

Versuch über ein neues Princip zur
Auffindung der Heilkrafte der
Arzneisubstanzen -*Hufeland's Journal* 2,
381, 1796



“Noi dobbiamo conoscere da una parte le malattie del corpo umano accuratamente, dall'altra gli effetti puri dei farmaci, cioè le caratteristiche essenziali ed i sintomi di quelle specifiche malattie artificiali che essi inducono. In questo modo, scegliendo per una certa malattia naturale quel rimedio che è capace di produrre una malattia artificiale molto simile noi saremo capaci di curare le malattie più ostinate”








Developments of experimental studies on APIS M.

- 1975- > High dilutions (7C-9C) of bee venom (*Apis mellifera* and *Apium virus*, which are currently used in homeopathy to treat skin manifestations with edema, erythema and pruritus) have a protective and curative effect on about 50% of X-ray induced erythema in albino guinea pig (BASTIDE1975, BILDET1989, 1990, POITEVIN1988)
- 1993 > Our group studied the effects of homeopathic preparations of *Apis mellifera* (and *Histamin*) on rat paw edema induced by the injection of inflammatory doses of histamine. It was observed that high dilutions of up to 30D had a small but significant inhibitory effect on the development of edema (Conforti et al., 1993).
- 2004 > We confirmed a small regulating effect of *Apis mellifera* (4 D, oral drops) in the carrageenan-induced edema in rats but could not reproduce it in blind trial (Conforti et al., 2004) probably for technical reasons (animals with different treatment in the same cage)
- 2014 > Bigagli and coworkers (2014) showed with microarray techniques that *Apis mellifera* TM modifies expression of hundreds of genes in human prostate epithelial cells; dynamized dilutions (3C, 5C and 7C) still exert significant effects on genes involved in inflammation and oxidative stress





EXAMPLES OF INVERSE EFFECTS WITH HOMEOPATHIC DILUTIONS IN LABORATORY SYSTEMS



| System | Agent | “High dose” effect | “Homeopathic” effect | Ref. |
|----------------------------------|--|--|---|---|
| Basophils | Histamine Apis mellifica | Pro-inflammatory agents | Histamine (up to 60x) and Apis mellifica (10c) | Poitevin 1988, S.Laudy 1991, Belon 1996-2004 |
| Rat, Guinea pig | Histamine Lung Histamine Apis mellifica | Pro-inflammatory agent | Histamine (30x), Lung histamine (18c) and Apis mellifica (7c/10c) reduce inflammation symptoms | Bastide 1975, Poitevin 1988, Bildet 1990 Conforti 1993 |
| Rat, Mouse | Arsenic trioxide Arsenicum album | Whole body and liver toxicity | Arsenic trioxide (7c and 17c) and Arsenicum album (30c) protect from intoxication | Lapp 1955; Wurmser 1955; Cazin 1987; Cazin 1991; Khuda-Bukhsh 1998-2000 |
| Wheat, hepatoma cells | Arsenic trioxide (As ₂ O ₃) | Cell toxicity | As₂O₃ 40x, 42x and 45x, stimulate germination and cell vitality | Betti 1997-2000, Wiegant-van Wijk 1998-2011 |
| Rat liver | Phosphorus | Hepatotoxicity | Phosphorus (30x) protects from toxic hepatitis | Bildet 1984, Guillemain 1987 Palmerini 1993 Gomez 1999 |
| Tadpoles | Thyroxine | Increases the rate of metamorphosis | High dilutions (up to 30x) inhibit the metamorphosis | Endler 1990-2010, Graunke 2007, Welles 2007, Lingg 2008, Weber 2008, Guedes 2011, Harrer 2013 |
| Mouse, rat | Gelsemium sempervirens | Toxic and convulsivant | Anxiolytic effect (2C-9C) | Marrari 2010, Gahlot 2012, Meyer 2013. |
| Human and rat neurons | Gelsemium sempervirens | Toxic and convulsivant | No toxicity, gene down-regulation | Venard 2011, Olioso 2014, Marzotto 2014 |



RESEARCH ARTICLE

Open Access

Extreme sensitivity of gene expression in human SH-SY5Y neurocytes to ultra-low doses of *Gelsemium sempervirens*

Marta Marzotto¹, Debora Olioso¹, Maurizio Brizzi², Paola Tononi³, Mirco Cristoforetti¹ and Paolo Bellavite^{1*}

Abstract

Background: *Gelsemium sempervirens* L. (*Gelsemium s.*) is a traditional medicinal plant, employed as an anxiolytic at ultra-low doses and animal models recently confirmed this activity. However the mechanisms by which it might operate on the nervous system are largely unknown. This work investigates the gene expression of a human neurocyte cell line treated with increasing dilutions of *Gelsemium s.* extract.

Methods: Starting from the crude extract, six 100 × (centesimal, c) dilutions of *Gelsemium s.* (2c, 3c, 4c, 5c, 9c and 30c) were prepared according to the French homeopathic pharmacopoeia. Human SH-SY5Y neuroblastoma cells were exposed for 24 h to test dilutions, and their transcriptome compared by microarray to that of cells treated with control vehicle solutions.

Results: Exposure to the *Gelsemium s.* 2c dilution (the highest dose employed, corresponding to a gelsemine concentration of 6.5×10^{-9} M) significantly changed the expression of 56 genes, of which 49 were down-regulated and 7 were overexpressed. Several of the down-regulated genes belonged to G-protein coupled receptor signaling pathways, calcium homeostasis, inflammatory response and neuropeptide receptors. Fisher exact test, applied to the group of 49 genes down-regulated by *Gelsemium s.* 2c, showed that the direction of effects was significantly maintained across the treatment with high homeopathic dilutions, even though the size of the differences was distributed in a small range.


Conclusions: The study shows that *Gelsemium s.*, a medicinal plant used in traditional remedies and homeopathy, modulates a series of genes involved in neuronal function. A small, but statistically significant, response was detected even to very low doses/high dilutions (up to 30c), indicating that the human neurocyte genome is extremely sensitive to this regulation.






Our model system

SHSY5Y neurocytes-human
neuroblastoma cells




Inverted microscope image



Confocal immunofluorescent
image



Our model system




Variation in the concentration of intracellular calcium in SHSY5Y cells stimulated with different doses of **carbachol**








Microarray analysis of gene expression changes in human neurocytes





Microarray analysis of gene expression changes in human neurocytes



Exposure to the Gelsemium s. 2CH promoted the significant down-expression of 49 while 7 genes were overexpressed

Many of these 56 genes belong to:

- neuropeptide/receptor systems
- calcium signalling
- G-protein coupled transduction systems
- inflammatory pathways

DOWN

UP

| Gene ID | Transcript ID | Symbol | Log ₂ fold change | p ¹ | Description |
|---------|---------------|--------------|------------------------------|----------------|--|
| 7940 | AF000424 | LST1 | -0.84 | ± 0.14 0.04 | leukocyte specific transcript 1 |
| 390113 | NM_001004726 | OR4X1 | -0.83 | ± 0.06 0.01 | olfactory receptor, family 4, subfamily X, member 1 |
| 23746 | AJ830742 | AIPL1 | -0.82 | ± 0.16 0.04 | aryl hydrocarbon receptor interacting protein-like 1 |
| 284498 | AL833920 | C1orf167 | -0.80 | ± 0.17 0.05 | chromosome 1 open reading frame 167 |
| 221191 | AK058068 | Klkb14 | -0.79 | ± 0.12 0.04 | plasma kalikrein-like protein 4 |
| 26658 | NM_012377 | OR7C2 | -0.77 | ± 0.07 0.01 | olfactory receptor, family 7, subfamily C, member 2 |
| 112401 | BC039318 | BIRC8 | -0.76 | ± 0.11 0.00 | baculoviral IAP repeat-containing 8 |
| 2848 | NM_005298 | GPR25 | -0.75 | ± 0.15 0.02 | G protein-coupled receptor 25 |
| 55803 | NM_018404 | ADAP2 | -0.75 | ± 0.11 0.02 | ArfGAP with dual PH domains 2 |
| 386676 | NM_198690 | KRTAP10-9 | -0.73 | ± 0.12 0.04 | keratin associated protein 10-9 |
| 4353 | X04876 | MPO | -0.72 | ± 0.15 0.04 | Myeloperoxidase |
| N/A | AY358413 | N/A | -0.71 | ± 0.18 0.02 | Homo sapiens clone DNA59853 trypsin inhibitor |
| 392391 | NM_001001923 | OR5C1 | -0.71 | ± 0.05 0.04 | olfactory receptor, family 5, subfamily C, member 1 |
| N/A | AK094115 | N/A | -0.70 | ± 0.11 0.04 | Homo sapiens cDNA FLJ36796 fis, clone ADRGL2006817 |
| 55287 | BC020658 | TMEM40 | -0.70 | ± 0.15 0.02 | transmembrane protein 40 |
| 54209 | NM_018965 | TREM2 | -0.69 | ± 0.10 0.02 | triggering receptor expressed on myeloid cells 2 |
| 150365 | AK097834 | RP5-821D11.2 | -0.68 | ± 0.17 0.02 | similar to mouse meiosis defective 1 gene |
| 400934 | NM_207478 | FLJ44385 | -0.68 | ± 0.09 0.04 | FLJ44385 protein |
| 255061 | NM_170685 | TAC4 | -0.67 | ± 0.14 0.01 | tachykinin 4 (hemokinin) |
| 644065 | NM_931993 | LOC644065 | -0.65 | ± 0.23 0.04 | hypothetical protein LOC644065 |
| 1339 | NM_005205 | COX6A2 | -0.64 | ± 0.17 0.01 | cytochrome c oxidase subunit VIa polypeptide 2 |
| N/A | AK128093 | N/A | -0.63 | ± 0.09 0.04 | Homo sapiens cDNA FLJ46214 fis, clone TESTI4012623. |
| 53841 | AY358368 | CDHR5 | -0.63 | ± 0.11 0.04 | mucin-like protocadherin |
| 9332 | NM_004244 | CD163 | -0.63 | ± 0.18 0.03 | CD163 molecule |
| 441239 | XM_499305 | LOC441239 | -0.63 | ± 0.22 0.05 | hypothetical gene supported by BC063653 |
| 7164 | NM_001003397 | TPD52L1 | -0.62 | ± 0.09 0.02 | tumor protein D52-like 1 |
| 11136 | NM_014270 | SLC7A9 | -0.62 | ± 0.09 0.04 | solute carrier family 7 member 9 |
| 389084 | NM_206895 | UNQ830 | -0.62 | ± 0.11 0.04 | ASCL830 |
| 400224 | NM_375090 | FLJ44817 | -0.62 | ± 0.20 0.04 | similar to pleckstrin homology domain protein (5V327) |
| 647240 | NM_934559 | LOC647240 | -0.60 | ± 0.06 0.00 | hypothetical protein LOC647240 |
| 846 | BC104999 | CASR | -0.59 | ± 0.06 0.00 | calcium-sensing receptor |
| 116123 | NM_138784 | RP11-45J16.2 | -0.58 | ± 0.09 0.04 | flavin-containing monooxygenase pseudogene |
| 644280 | XM_497769 | LOC644280 | -0.58 | ± 0.06 0.05 | hypothetical protein LOC644280 |
| 57452 | AB032956 | GALNT1 | -0.57 | ± 0.17 0.05 | alpha-D-galactosamine N-acetylgalactosaminyltransferase |
| 414301 | NM_001001711 | DDI1 | -0.56 | ± 0.11 0.04 | DDI1, DNA-damage inducible 1, homolog 1 (<i>S. cerevisiae</i>) |
| 116535 | BC016964 | MRGPRF | -0.55 | ± 0.17 0.01 | MAS-related GPR, member F |
| 8811 | NM_003857 | GALR2 | -0.55 | ± 0.07 0.04 | galanin receptor 2 |
| 10880 | NM_006686 | ACTL7B | -0.55 | ± 0.12 0.04 | actin-like 7B |
| 6368 | NM_145898 | CCL23 | -0.55 | ± 0.11 0.05 | chemokine (C-C motif) ligand 23 |
| 64581 | BC071746 | CLEC7A | -0.54 | ± 0.08 0.04 | C-type lectin domain family 7, member A |
| 644003 | NM_927256 | LOC644003 | -0.54 | ± 0.11 0.04 | similar to Mucin-2 precursor (Intestinal mucin 2) |
| 643514 | NM_931594 | LOC643514 | -0.54 | ± 0.10 0.03 | hypothetical protein LOC643514 |
| 374569 | NM_935431 | LOC374569 | -0.54 | ± 0.07 0.04 | Similar to Lysophospholipase |
| 84504 | BC101635 | NKX6-2 | -0.53 | ± 0.13 0.03 | NK6 transcription factor related, locus 2 (<i>Drosophila</i>) |
| 732 | NM_000066 | C8B | -0.53 | ± 0.06 0.05 | complement component 8, beta polypeptide |
| 146336 | NM_182510 | FLJ32252 | -0.52 | ± 0.03 0.01 | hypothetical protein FLJ32252 |
| 150763 | BC042847 | LOC150763 | -0.51 | ± 0.10 0.04 | hypothetical protein LOC150763 |
| 2020 | NM_001427 | EN2 | -0.51 | ± 0.08 0.04 | engrailed homolog 2 |
| 646258 | NM_929203 | LOC646258 | -0.51 | ± 0.11 0.04 | hypothetical protein LOC646258 |
| 154872 | NM_001024603 | LOC154872 | 0.51 | ± 0.10 0.03 | hypothetical LOC154872 |
| 400866 | NM_001001789 | C21orf24 | 0.52 | ± 0.12 0.05 | chromosome 21 open reading frame 24 |
| 9457 | NM_020482 | FHL5 | 0.55 | ± 0.19 0.04 | four and a half LIM domains 5 |
| 55816 | NM_018431 | DOK5 | 0.56 | ± 0.04 0.03 | docking protein 5 |
| 1446 | NM_001890 | CSN1S1 | 0.57 | ± 0.09 0.04 | casein alpha s1 |
| 285600 | AK130941 | KIAA0825 | 0.63 | ± 0.06 0.01 | KIAA0825 protein |
| 57538 | NM_020778 | ALPK3 | 0.76 | ± 0.10 0.01 | alpha-kinase 3 |

Effects of Gelsemium on expression of 49 Gels C2-down-regulated genes

[Gelsemine]=
 1.3×10^7
molecule/cell







1.3×10^3
molecule/cell

0 molecule/cell



1.3×10^5
molecule/cell

13
molecules/cell

0 molecule/cell




RT-Array su panel di geni di recettori



RT-Array on



Gelsemium
sempervirens L.



Nei neuroni umani in coltura 49 GENI su of 45034 testati sono regolati da alte diluizioni/dinamizzazioni di *Gelsemium sempervirens*




L'espressione genica

- È sensibile a informazioni di bassissima energia
- È complessa e olografica
- È influenzata dallo stato del mezzo acquoso

NUOVO SPAZIO PER UNA OMEOPATIA SCIENTIFICA!

L'espressione genica

- È individualizzata per definizione (polimorfismi)
- È influenzata dinamicamente dalla storia patobiografica (epigenetica)



Grazie a Lui
dell'ispirazione



Grazie a Voi
dell'attenzione!

Cimitero Père Lachais
Paris, 30 marzo 2013

